Recent advances in the molecular landscape of lung neuroendocrine tumors.


Journal

Expert review of molecular diagnostics
ISSN: 1744-8352
Titre abrégé: Expert Rev Mol Diagn
Pays: England
ID NLM: 101120777

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 23 3 2019
medline: 27 5 2020
entrez: 23 3 2019
Statut: ppublish

Résumé

Neuroendocrine tumors of the lung (Lung-NETs) make up a heterogenous family of neoplasms showing neuroendocrine differentiation and encompass carcinoids and neuroendocrine carcinomas. On molecular grounds, they considered two completely distinct and separate tumor groups with no overlap of molecular alterations nor common developmental mechanisms. Areas covered: Two perspectives were evaluated based on an extensive review and rethinking of literature: (1) the current classification as an instrument to obtaining clinical and molecular insights into the context of Lung-NETs; and (2) an alternative and innovative interpretation of these tumors, proposing a tripartite separation into early aggressive primary high-grade neuroendocrine tumors (HGNET), differentiating or secondary HGNET, and indolent NET. Expert opinion: We herein provide an alternative outlook on Lung-NETs, which is a paradigm shift to current pathogenesis models and expands the understanding of these tumors.

Identifiants

pubmed: 30900485
doi: 10.1080/14737159.2019.1595593
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-297

Auteurs

Giuseppe Pelosi (G)

a Department of Oncology and Hemato-Oncology , University or Milan , Milan , Italy.
b Inter-hospital Pathology Division , Institute for Research and Care-IRCCS MultiMedica , Milan , Italy.

Fabrizio Bianchi (F)

c Cancer Biomarkers Unit, Foundation for Research and Care-IRCCS "Casa Sollievo della Sofferenza" , Foggia , Italy.

Paul Hofman (P)

d Laboratory of Clinical and Experimental Pathology , FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN, Inserm U1081 CNRS 7284, University Côte d'Azur , Nice , France.

Linda Pattini (L)

e Department of Electronics , Information and Bioengineering, Polytechnic of Milan , Milan , Italy.

Philipp Ströbel (P)

f Institute of Pathology , University Medical Center Göttingen , Göttingen , Germany.

Fiorella Calabrese (F)

g Department of Cardiac, Thoracic and Vascular Sciences , University of Padua , Padua , Italy.

Salma Naheed (S)

h Cancer Sciences Unit, Faculty of Medicine , University of Southampton , Southampton , UK.

Chloe Holden (C)

i Department of Medical Oncology , Royal Bournemouth and Christchurch Hospitals NHS Trust , Bournemouth , UK.

Judith Cave (J)

j Department of Medical Oncology , University Hospital Southampton NHS FT , Southampton , UK.

Hanibal Bohnenberger (H)

f Institute of Pathology , University Medical Center Göttingen , Göttingen , Germany.

Helen Dinter (H)

f Institute of Pathology , University Medical Center Göttingen , Göttingen , Germany.

Sergio Harari (S)

k Department of Medical Sciences and Division of Pneumology, San Giuseppe Hospital , Institute for Research and Care-IRCCS MultiMedica , Milan , Italy.

Adriana Albini (A)

l Laboratory of Vascular Biology and Angiogenesis , Institute for Research and Care-IRCCS MultiMedica , Milan , Italy.

Angelica Sonzogni (A)

m Department of Pathology and Laboratory Medicine , Foundation for Research and Care-IRCCS National Cancer Institute , Milan , Italy.

Mauro Papotti (M)

n Department of Oncology , University of Turin , Turin , Italy.

Marco Volante (M)

o Department of Oncology , University of Turin and Pathology Unit San Luigi Hospital , Turin , Italy.

Christian H Ottensmeier (CH)

p Christian CRUK and NIHR Southamtpon Experimental Cancer Medicine Centre, Faculty of Medicine , University of Southampton , Southampton , UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH